Corpus overview


MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Systematic Review and Meta-analysis of the Safety of Chloroquine and Hydroxychloroquine From Randomized Controlled Trials on Malarial and Non-malarial Conditions

    Authors: Mayra Souza Botelho; Fernanda Bolfi; Renata Giacomini Occhiuto Ferreira Leite; Mauro Salles Ferreira Leite; Luisa Rocco Banzato; Luiza Teixeira Soares; Thaina Oliveira Felicio Olivatti; Amanda Sampaio Mangolim; Flávia Ramos Kazan Oliveira; Luciana Patrícia Fernandes Abbade; Joelcio Francisco Abbade; Ricardo Augusto Monteiro de Barros Almeida; Julia Simões Correa Galendi; Lehana Thabane; Vania dos Santos Nunes Nogueira

    doi:10.21203/ Date: 2020-09-10 Source: ResearchSquare

    Background: Despite the expectations regarding the effectiveness of chloroquine (CQ) and hydroxychloroquine (HCQ) for coronavirus disease MESHD ( COVID-19 MESHD) management, concerns about their adverse events have remained. Objectives: The objective of this systematic review was to evaluate the safety of CQ and HCQ from malarial and non-malarial randomized clinical trials (RCTs). Methods: The primary outcomes were the frequencies of serious adverse events ( SAEs MESHD), retinopathy MESHD, and cardiac complications MESHD. Search strategies were applied to MEDLINE, EMBASE, LILACS, CENTRAL, Scopus, and Trip databases. We used random-effects model to pool results across studies and Peto one-step odds ratio (OR) for event rates below 1 %. Both-armed zero-event studies were excluded from the meta-analyses. We used the Grading of Recommendations Assessment, Development, and Evaluation system to evaluate the certainty of evidence.Results: Ninety-two RCTs were included. We found no significant difference between CQ/HCQ and control (placebo or non-CQ/HCQ) in the frequency of SAEs MESHD (OR: 0.98, 95 % confidence interval [CI]: 0.71–1.36, 25 trials, 11,605 participants, moderate certainty of evidence). No clear relationship was observed between CQ/HCQ and retinopathy MESHD (OR: 1,63, 95 % CI: -0.4–6.57, 5 trials, 344 participants, very low certainty of evidence). There was a low certainty of evidence of the effect of CQ/HCQ versus control on cardiac complications (Relative risk: 1.48, 95 % CI: 1.1–1.98, 8 trials, 5,970 participants).Conclusions: CQ and HCQ might be safe, with low frequency of SAEs on malarial and non-malarial conditions MESHD. No clear effect of their use on the incidence of retinopathy and cardiac complications MESHD was observed.The protocol for this systematic review was registered with PROSPERO (registration number: CRD42020177818)

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.